

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BeOne Medicines Ltd.

百濟神州有限公司

(a corporation incorporated under the laws of Switzerland)

(Stock Code: 06160)

VOLUNTARY ANNOUNCEMENT – BUSINESS UPDATE

Reference is made to the announcements of BeOne Medicines Ltd. (“**BeOne**” or the “**Company**”) dated June 16, 2023 and April 30, 2025 in relation to patent infringement allegations by Pharmacyclics LLC (“**Pharmacyclics**”).

The Company hereby announces that Pharmacyclics decided not to appeal the Final Written Decision rendered by the U.S. Patent and Trademark Office, which invalidated all claims of Pharmacyclics’ U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeOne in a post-grant review proceeding. On September 30, 2025 (U.S. Time), BeOne and Pharmacyclics filed a joint stipulation to voluntarily dismiss the related district court litigation with prejudice. Accordingly, this matter has been fully resolved.

By order of the Board
BeOne Medicines Ltd.
Mr. John V. Oyler
Chairman

Hong Kong, October 2, 2025

As of the date of this announcement, the Board of Directors of the Company consists of Mr. John V. Oyler as Chairman and Executive Director, Dr. Xiaodong Wang as Non-executive Director, and Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Michael Goller, Mr. Anthony C. Hooper, Mr. Ranjeev Krishana, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders, Ms. Shalini Sharp and Mr. Qingqing Yi as Independent Non-executive Directors.